117 institutions hold shares in Abeona Therapeutics Inc. (ABEO), with 16.02M shares held by insiders accounting for 16.22% while institutional investors hold 45.27% of the company’s shares. The shares outstanding are 91.06M, and float is at 84.39M with Short Float at 6.85%. Institutions hold 37.93% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Adage Capital Partners GP L.L.C. with over 8.29 million shares valued at $13.01 million. The investor’s holdings represent 8.39% of the ABEO Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 4.09 million shares valued at $6.42 million to account for 4.14% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 3.18 million shares representing 3.22% and valued at over $4.99 million, while Citadel Advisors LLC holds 2.91% of the shares totaling 2.87 million with a market value of $4.51 million.
Abeona Therapeutics Inc. (NASDAQ: ABEO) is 14.01% higher on its value in year-to-date trading and has touched a low of $0.99 and a high of $3.79 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ABEO stock was last observed hovering at around $1.80 in the last trading session, with the day’s loss setting it -0.01% off its average median price target of $5.00 for the next 12 months. It is also 77.63% off the consensus price target high of $8.00 offered by 3 analysts, but current levels are 55.25% higher than the price target low of $4.00 for the same period.
Currently trading at $1.79, the stock is -16.22% and -22.02% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.9 million and changing -0.56% at the moment leaves the stock -14.56% off its SMA200. ABEO registered -13.11% loss for a year compared to 6-month gain of -3.76%. The firm has a 50-day simple moving average (SMA 50) of $2.3765 and a 200-day simple moving average (SMA200) of $1.7699.
The stock witnessed a -26.03% loss in the last 1 month and extending the period to 3 months gives it a 3.47%, and is -12.25% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.07% over the week and 9.64% over the month.
Abeona Therapeutics Inc. (ABEO) has around 76 employees, a market worth around $184.67M and $10.00M in sales. Distance from 52-week low is 80.90% and -52.77% from its 52-week high. The company has generated returns on investments over the last 12 months (-78.10%).
Abeona Therapeutics Inc. (ABEO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Abeona Therapeutics Inc. (ABEO) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Abeona Therapeutics Inc. is expected to release its quarterly report on 05/07/2021 and quarterly earnings per share for the current quarter are estimated at -$0.18.The EPS is expected to grow by 40.00% this year, but quarterly earnings will post -95.00% year-over-year.
Abeona Therapeutics Inc. (ABEO) Insider Activity
A total of 36 insider transactions have happened at Abeona Therapeutics Inc. (ABEO) in the last six months, with sales accounting for 21 and purchases happening 15 times. The most recent transaction is an insider sale by SCO CAPITAL PARTNERS LLC, the company’s Director. SEC filings show that SCO CAPITAL PARTNERS LLC sold 80,000 shares of the company’s common stock on Mar 18 at a price of $2.23 per share for a total of $0.18 million. Following the sale, the insider now owns 11.16 million shares.
Abeona Therapeutics Inc. disclosed in a document filed with the SEC on Feb 19 that Wider Todd (Director) sold a total of 251,625 shares of the company’s common stock. The trade occurred on Feb 19 and was made at $2.39 per share for $0.6 million. Following the transaction, the insider now directly holds 25000.0 shares of the ABEO stock.
Still, SEC filings show that on Feb 19, Mann Paul Elliot (Director) disposed off 45,566 shares at an average price of $2.38 for $0.11 million. The insider now directly holds 0 shares of Abeona Therapeutics Inc. (ABEO).
Abeona Therapeutics Inc. (ABEO): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 34.82% up over the past 12 months and Madrigal Pharmaceuticals Inc. (MDGL) that is 67.67% higher over the same period. Ironwood Pharmaceuticals Inc. (IRWD) is 10.31% up on the 1-year trading charts. Short interest in the company’s stock has risen 48.96% from the last report on Feb 11, 2021 to stand at a total of 2.95 million short shares sold with a short interest ratio of 1.14.